ClinicalTrials.gg
RecruitingNCT06798571Updated Oct 2, 2026

Role of Menopause in Thermoregulation

A Phase 4 interventional study of Elagolix Oral Tablet and Estradiol patch in Menopause and Aging, sponsored by Penn State University. Recruiting at 1 site in United States. Open to female participants aged 42 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Penn State University · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
42 Years to 64 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Heat Stress Disorders with a site in United States — 11 open to participants now, 13 under way, none of them phase 3. Heat Stress Disorders · United States.

Planned enrollment
14th of 27
24 · median 24
Started
2025
with 8 others
Phase 4
2 of 33
2 open now
Primary completion
2026-12
later than 5 of 12 live
Registered
20th of 33
by date
Lead sponsor
4 of 33
Penn State University

Among the 33 studies in Heat Stress Disorders with a site in United States, this one is the 14th largest by planned enrollment of the 27 interventional ones that give a count, is one of 9 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 5 of the 12 other live ones, and was the 20th registered.

Heat Stress Disorders

118 studies on the registry are indexed under Heat Stress Disorders; 42 are open to participants now.

Browse Heat Stress Disorders studies →

Open to participants now

11 of the 33 studies in Heat Stress Disorders with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Heat Stress Disorders studies recruiting now, 8 (27%) set no upper age limit and 18 (60%) stop at 75 or younger; 6 take children under 18; 22 take healthy volunteers.

This study: 42 Years to 64 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Heat Stress Disorders with a site in United States, or all of them as a file.
02

Study summary

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men.

Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Read the detailed description

Premenopausal and postmenopausal women will be recruited and different interventions will be given to each group. To mimic a postmenopausal hormone profile, premenopausal women will be given a GnRH antagonist, which acutely reduces estrogen concentrations. This induces a temporary post-menopausal state without compounding aging effects. Postmenopausal women will be given a transdermal estradiol patch to acutely raise estrogen concentrations. Supplementing estrogen in postmenopausal women allows for the effect of menopausal low estrogen concentration to be removed from the physiological effects of aging.

Subjects sign an informed consent form and undergo a medical screening prior to participation. The screening includes a physical exam, anthropometry, chemical and lipid profiles.

Each subject will complete 6 (3 for each treatment) experimental trials. For each intervention, participants will complete one passive heating experiment first, followed by two active heating experiments.

03

Conditions studied

  • Menopause
  • Aging

Browse trials for

Keywords

  • Thermoregulation
  • Heat Stress
04

Who can participate

Ages eligible
42 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women ages 42-64

Exclusion criteria

Exclusion Criteria:

  • Chron's disease, diverticulitis, or similar gastrointestinal disease
  • Abnormal resting exercise (ECG)
  • Tobacco use
  • High-risk determined by the Atherosclerotic Cardiovascular Disease (CVD) Risk Factor
  • Assessment
  • Using hormone therapy
  • Using hormonal
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Premenopausal estrogen suppression

    Participants take a cellulose placebo tablet for 4 days prior to baseline testing and continue until experimental visits are complete. Following completion of placebo testing, participants begin taking 400 mg/day Elagolix for 4 days prior to testing and continue until experimental visits are complete.

    Drug: Elagolix Oral Tablet · Other: cellulose placebo

  • Experimental
    Postmenopausal estrogen supplementation

    Participants wear a transdermal estradiol patch or placebo patch for 5 days prior to testing and continue until experimental visits are complete. After 48 hr washout, participants then wear the alternative treatment for 5 days prior to testing until experimental visits are complete.

    Drug: Estradiol patch · Other: placebo patch

Interventions

06

What researchers measure

Primary outcomes

  1. Skin Blood Flow

    Skin blood flow response to whole body heating is continuously monitored

    Time frame: Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)

  2. Local Sweat Rate

    A small sweat capsule is placed on the forearm for the duration of whole body heating.

    Time frame: Monitored continuously during both 3 hour passive heating experiments (Visit 1 and Visit 3 approx 3 weeks)

  3. Core Temperature

    Changes in body temperature are measured through a telemetry pill swallowed before each experiment.

    Time frame: Monitored continuously during all 3 hour experimental visits (6 total average of 3 weeks)

Secondary outcomes

  1. Body Mass

    Body mass is measured on a scale.

    Time frame: Baseline and following 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)

  2. Skin Temperature

    Mean skin temperature is calculated from a weighted average of skin temperature from 4 different sites.

    Time frame: Calculated continuously for the duration of each 3 hr experimental visit (6 total visits for study completion, an average of 3 weeks)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 29, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 1, 2026was Sep 2026
CompletionEst.
Dec 1, 2026was Sep 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→Dec 1, 2026
Oct 2, 2026
Study completion
Sep 1, 2026→Dec 1, 2026
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Sep 1, 2026→Dec 1, 2026
    Study completion Sep 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06798571
Responsible party
W. Larry Kenney (Professor, Penn State University) — Principal investigator
First posted
Jan 29, 2025
Start date
Mar 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

W. Larry Kenney, Ph.D.
Contact
w7k@psu.edu
814-863-1672
Olivia K. Leach, MS
Contact
okl5046@psu.edu
W. Larry Kenney, Ph.D.
principal investigator · The Pennsylvania State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elagolix · Estradiol

Start the discussion